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Abstract
AIM: To evaluate the clinical significance of cystatin C 
and renal resistive index for the determination of renal 
function in patients with liver cirrhosis.
METHODS: We conducted a study of 63 patients with 
liver cirrhosis. A control group comprised of 30 age and 
gender-matched healthy persons. Serum cystatin C 
was determined in all study subjects and renal Doppler 
ultrasonography was made. Estimated glomerular filtra-
tion rate from serum creatinine (GFRCr) and cystatin C 
(GFRCys) was calculated.
RESULTS: We confirmed significant differences in val-
ues of cystatin C between patients with different stages 
of liver cirrhosis according to Child-Pugh (P  = 0.01), 
and a significant correlation with model of end stage 
liver disease (MELD) score (r s = 0.527, P  < 0.001). More 
patients with decreased glomerular filtration rate were 
identified based on GFRCys than on GFRCr (P  < 0.001). 
Significantly higher renal resistive index was noted in 
Child-Pugh C than in A (P  < 0.001) and B stage (P  = 
0.001). Also, a significant correlation between renal re-
sistive index and MELD score was observed (r s = 0.607, 
P  < 0.001). Renal resistive index correlated significantly 
with cystatin C (r s = 0.283, P  = 0.028) and showed a 
negative correlation with GFRCys (r s = -0.31, P  = 0.016). 
CONCLUSION: Cystatin C may be a more reliable 
marker for assessment of liver insufficiency. Additional-
ly, cystatin C and renal resistive index represent sensi-
tive indicators of renal dysfunction in patients with liver 
cirrhosis.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
Key words: Liver cirrhosis; Cystatin C; Renal resistive 
index
Core tip: Early diagnosis of renal dysfunction is important 
to prevent serious complications. We conducted a study 
of 63 patients with liver cirrhosis and 30 healthy controls. 
Serum cystatin C (CysC) was measured and renal Dop-
pler ultrasonography was performed. More patients with 
decreased glomerular filtration rate (GFR) were identi-
fied based on CysC GFR than on creatinine GFR. Higher 
renal resistive index in advanced disease by Child-Pugh 
and model of end stage liver disease was noticed. Renal 
resistive index (RRI) correlated with CysC and negatively 
correlated with glomerular filtration rate from serum cys-
tatin C. Cystatin C may be a more reliable marker for liver 
insufficiency assessment. CysC and RRI represent sensi-
tive indicators of renal dysfunction in liver cirrhosis.
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INTRODUCTION
Cirrhosis of  the liver is often accompanied by functional 
renal failure particularly in advanced stages of  liver dis-
ease. Hemodynamic alterations with reduced effective 
arterial blood volume and peripheral vasodilation are fol-
lowed by activation of  vasoconstrictive hormones (renin-
aldosterone, vasopresin, endothelin) and neurohumoral 
systems (including increased activity of  nervous sys-
tem)[1,2]. The most common functional renal abnormalities 
in patients with cirrhosis are an impaired ability to excrete 
sodium and water and a reduction of  renal blood flow and 
glomerular filtration rate, the latter two being secondary 
to vasoconstriction of  the renal circulation[3]. Hence renal 
failure is directly linked to the mortality rate of  cirrhotic 
patients, it is of  a great clinical importance to monitor re-
nal function closely in order to estimate the prognosis and 
determine the optimal therapeutic option[4].
Whereas patients with a significantly impaired glo-
merular filtration rate can be diagnosed easily by elevated 
serum creatinine (Cr) concentrations, moderately reduced 
renal function may go unnoticed by this conventional 
parameter. Nevertheless, the protease inhibitor cystatin 
C (CysC) has been proposed as a specific marker of  glo-
merular filtration rate (GFR) and an early indicator of  
impaired renal function[5].
CysC is a non-glycosylated 13 kDa protein, produced 
at a constant rate by all nucleated cells, freely filtered 
by the glomeruli and subsequently metabolized in the 
proximal tubules[6]. Opposed to Cr, CysC is independent 
of  gender, age, and muscle mass and not influenced by 
serum bilirubin, inflammation, or malignancy[7,8].
The aim of  the study was to evaluate the clinical sig-
nificance of  CysC and renal blood flow for the determi-
nation of  renal function in patients with liver cirrhosis.
MATERIALS AND METHODS
Subjects
We conducted a study of  63 patients, aged 18 years and 
above, with alcoholic or viral liver cirrhosis examined and 
treated between December 2011 and September 2013 at 
the Clinic for Gastroenterology and Hepatology, Clinical 
Center of  Serbia, Belgrade. A healthy control group com-
prised of  30 age and gender-matched subjects. Diagnos-
tic approach was based on clinical clues from the patient’
s medical history (e.g., consumption of  pure alcohol more 
than 50 g/d over a five-year period), physical examina-
tion, laboratory tests, abdominal ultrasonography and up-
per endoscopy; liver biopsy was performed in 15 (23.8%) 
patients. Laboratory analyses included tests of  hepatocyte 
integrity, cholestasis, synthetic liver function tests and 
etiological tests.
The degree of  liver insufficiency was assessed accord-
ing to the Child-Pugh classification and divided into three 
stages: A, B and C (score A ≤ 6, B 7-9, and C ≥ 10)[9]. The 
diagnosis of  hepatic encephalopathy was based on clini-
cal criteria, and the severity of  hepatic encephalopathy 
was based on the West Haven Criteria for grading of  
mental status[10]. The model of  end stage liver disease 
(MELD) has also been used to assess patients with liver 
cirrhosis[11]. 
All respondents were evaluated for any superimposed 
conditions such as infection, intrinsic renal disease, 
chronic obstructive pulmonary disease, congestive heart 
failure, thyroid dysfunction, and diabetes mellitus. The 
following exclusion criteria were applied: patients with 
hepatocellular carcinoma, gastrointestinal bleeding, or 
hepatorenal syndrome (HRS). Patients receiving cortico-
steroids, antiviral agents, angiotensin Ⅱ receptor blockers, 
angiotensin-converting enzyme inhibitors, amynoglicosi-
des, nonsteroidal anti-inflamatory drugs, or aminoacids 
L-arginine and L- ornithine were also excluded from the 
study. 
Biochemistry
Diuretics were stopped in all patients, at least 24 h before 
laboratory testing. Patients were adviced to adopt a low-
sodium diet (less than 40 mmol/d). Serum samples were 
obtained on the day of  urine collection. Venous blood 
samples were collected in vacutainers without additives, 
centrifuged at 3500 rpm (about 2000 g) and preserved at 
-80 ℃ after separation. CysC serum concentration was 
determined by the PENIA method (Particle-Enhancesd 
Nephelometric Immuno-Assay), using the SIEMENS 
(Marburg, Germany) tests, on a laser nephelometer (BN 
IIDadeBehring). CysC referent value was 0.59-1.04 mg/L. 
Cr was determined according to the kinetic Jaffe’s meth-
od, using an automated biochemical analyzer (Olympus 
AU 400) and commercially available assay kits by the 
same manufacturer. Cr referent value for men was 59-104 
µmol/L and for women 45-84 µmol/L. Creatinine clear-
ance (CLCr) was calculated as a product of  urinary Cr 
and 24-h urine volumen divided by serum Cr (µmol/L) 
and multiplied by 1440. Referent values for 24-h urinary 
creatinine excretion were 23 mg/kg ideal body weight for 
men and of  17 mg/kg ideal body weight for women[12].
Estimated GFR was calculated from serum Cr us-
ing the Modification of  Diet in Renal Disease (MDRD) 
equation: eGFR = 186 × sCr-1.154 × age-0.203 × 1.212 (if  
African American) × 0.742 (if  female)[13], and from se-
rum CysC using Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation: eGFR = 127.7 × 
CysC-1.17 × age-0.13 × 0.91 (if  female) × 1.06 (if  African 
American)[14]. Serum sodium (sNa+) referent value was 
135-148 mmol/L, and urine sodium (uNa+) referent val-
ue for men was 40-220 mmol/L and for women 27-287 
mmol/L.
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Abdominal and renal Doppler ultrasonography
Ultrasonography (Toshiba Core Vision, with Doppler 
duplex convex probe, 3.5 MHz) was performed to 
examine the liver size, echo structure of  the hepatic 
parenchyma and possible focal changes, spleen diameter, 
and presence of  ascites. Renal color Doppler duplex 
ultrasonography was used to evaluate renal resistive 
index (RRI). The renal arteries were evaluated bilaterally 
of  the distal arcuate branches. RRI equals peak systolic 
velocity minus the final diastolic velocity divided by the 
peak systolic velocity. RRI less than 0.7 is considered 
normal and was calculated based on the mean value of  
renal arteries[15,16].
Statistical analysis
One-sample Kolmogorov-Smirnov and Shapiro-Wilk 
tests were performed to determine whether the data 
showed normal distribution. t test or Mann-Whitney 
test was applied to assess the differences in investigated 
parameters. Analysis of  variance (ANOVA) or Kruskal-
Wallis test was applied to assess the influence of  the 
investigated parameters. After assessing overall effects 
of  a factor by means of  ANOVA, post-hoc multiple 
comparison procedures with Bonferonni correction were 
performed to determine individual differences between 
the groups. Pearson’s (r) or Spearman’s correlation (rs) 
procedures were performed to evaluate the relationship 
between different variables. McNemar’s test was used to 
assess the differences in detecting renal function using 
two different approaches. The Statistical Package for So-
cial Sciences version 15 (SPSS Inc., Chicago, IL, United 
States) was used for statistical analyses, at the 0.05 level 
of  significance. 
Ethical considerations
The study was conducted in accordance with Guidelines 
for Good Clinical Practice, the Declaration of  Helsinki, 
and local laws and regulations. The protocol was ap-
proved by joint Research and Ethics Committee of  the 
Clinical Center of  Serbia, Belgrade, filed under number 
2385/5. Written informed consent was obtained from all 
the participants in the study.
RESULTS
The patient group comprised 47 (74.6%) males and 16 
(25.4%) females. The average age of  the patients was 50.8 
± 13.5. Alcoholic cirrhosis was diagnosed in 41 (65.1%) 
and viral cirrhosis in 22 (34.9%) patients.
The average value of  CysC measured in patients with 
liver cirrhosis was 1.09 ± 0.42 mg/L, while it was 0.88 ± 
0.12 mg/L in the control group. Comparing these groups, 
we have confirmed significantly higher CysC in patients 
with cirrhosis (P = 0.036). Increased values of  CysC were 
observed in 23 (40%) patients.
The liver insufficiency degree, determined by gener-
ally accepted Child-Pugh classification, was divided into 
three stages: A in 23 (36.5%), B in 21 (33.3%) and C in 
19 (30.2%) patients. Patients’characteristics based on 
Child-Pugh score are presented in Table 1. MELD score 
ranged from 8 to 26.
Post-hoc comparisons showed statistically significant 
differences in values of  CysC between Child-Pugh A and 
B (P = 0.014) and between A and C (P = 0.007) stages, 
while there was no difference between B and C stages (P 
> 0.05) (Table 1). Moreover, we confirmed a statistically 
significant correlation between CysC and MELD score 
(Figure 1).
Increased Cr values were detected in 7 (11.1%) pa-
tients, and all of  them had increased values of  CysC. 
Mean values for 24-h urinary creatinine excretion for men 
was 18.3 mg/kg, and for women 16.3 mg/kg. Decreased 
creatinine values were detected in 32/47 (68%) men and 
9/16 (56.3%) women. There were no significant differ-
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Table 1  Characteristics of enrolled patients based on Child 
Pugh score (n  = 63)
Characteristic A B C P value
Bilirubin (µmol/L) 17.7      33.5      55.1 < 0.001
AST (U/L) 34   39   57    0.035
ALT (U/L) 32   29   40    0.187
ALP (U/L) 112 109 113    0.888
GGT (U/L) 103   73   51    0.153
Albumin (g/L) 36   32   25 < 0.001
sNa+ (mmol/L) 139 137 135    0.008
Cr (µmol/L) 67   70   74    0.540
CLCr (mL/min) 120.7 114 104    0.823
GFRCr (mL/min per 1.73 m2) 129.9    116.1 111    0.476
CysC (mg/L) 0.83          1.09          1.12    0.010
GFRCys(mL/min per 1.73 m2) 93.3      67.1      64.7    0.017
RRI 0.63        0.7          0.75 < 0.001
All data are presented as median values. AST: Aspartate aminotransferase; 
ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: 
Gamma-glutamyl transferase; sNa+: Serum sodium; Cr: Creatinine; CLCr: 
Creatinine clearance; GFRCr: Glomerular filtration rate based on creatinine; 
CysC: Cystatin C; GFRCys: Glomerular filtration rate based on cystatin C; 















































Figure 1  Correlation of renal parameters with model of end stage liver 
disease score. rs: Spearman’s rank correlation coefficient; CysC: Cystatin C 
(P < 0.001); Cr: Creatinine (P = 0.091); CLCr: Creatinine clearance (P = 0.557); 
GFRCr: Glomerular filtration rate based on creatinine (P = 0.460); GFRCys: 
Glomerular filtration rate based on cystatin C (P < 0.001); RRI: Renal resistive 
index (P < 0.001). 
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RRI in Child-Pugh stage C than in A (P < 0.001) and 
B stage (P = 0.001). Also, a significant correlation was 
noted between RRI and MELD (Figure 1).
RRI correlated significantly with CysC (rs = 0.283, P = 
0.028) and showed a significant negative correlation with 
GFRCys (rs = -0.31, P = 0.016). However, we detected no 
relationship between RRI and Cr, CLCr, or GFRCr.
DISCUSSION
Early diagnosis of  impaired renal function, particularly 
decreased GFR, is very important to prevent serious 
complications[5]. The gold standard for determining GFR 
is to measure the clearance of  an exogenous substances 
such as chromium-51 labeled ethylenediamine tetraacetic 
acid (51Cr-EDTA) and inulin. Procedures determining 
GFR using exogenous substances are invasive and carry 
a risk for patients, usually are considered too expensive 
and time consuming for routine clinical use[17]. Moreover, 
procedure for measuring inulin clearance is impractical 
because of  the necessity for steady-state infusion, a urine 
bladder catheter, and possible interference from blood 
glucose[18].
The endogenous marker of  GFR most commonly 
used in routine clinical and laboratory practice is serum 
Cr. However, in liver cirrhosis, specific non-renal factors 
may influence Cr concentration. Protein-calorie malnu-
trition, muscle wasting, and impaired liver function will 
directly reduce Cr production[19]. Moreover, ascites and 
peripheral edema can also decrease the Cr due to larger 
area for distribution[20,21]. We report that reduced urinary 
creatinine excretion in cirrhosis correlates with anthropo-
metrically estimated muscle mass and is not related to 
reduced liver function. Our results are consistent with a 
previous study conducted by Pirlich et al[22]. Given the fact 
that serum Cr systematically overestimates renal function, 
mild degree of  renal insufficiency may go unnoticed as 
Cr level may remain in the normal range despite a major 
decline in GFR[4,23]. Moreover, several studies have shown 
that CLCr overestimates true GFR about 13 mL/min per 
1.73 m2 compared to inulin clearance in patients with cir-
rhosis[24,25]. Variation in creatinine excretion exists during 
the day, making estimation of  GFR, even from a valid 
24-hour urine collection, incorrect[25].
Some studies have indicated that serum CysC could 
be proposed as a marker of  liver disease stage and a more 
sensitive indicator of  renal function in patients with cir-
rhosis than serum Cr level[26-28].
Particularly in patients with Child-Pugh class C, CysC 
determination is a valuable tool for the early diagnosis of  
moderately impaired renal function[5]. 
Significant differences were observed in CysC values 
but not Cr values, between Child-Pugh class A, B, and 
C. The finding suggests that CysC may indirectly reflect 
the degree of  liver dysfunction[22,29]. Woitas et al[30] found 
that CysC was significantly higher in Child-Pugh B and 
C patients when compared to Child-Pugh A patients. 
Still no difference was observed between patients with 
ences in Cr values between the stages of  liver cirrhosis in 
regards to Child-Pugh classification. Furthermore, we de-
tected no significant correlation between Cr and MELD 
score (Figure 1).
Decreased CLCr was detected in 24 (38%) patients 
with an average value of  57.2 ± 21.2 mL/min. Reduced 
CLCr in 9 out of  23 (39.1%) patients with Child-Pugh 
A, 8 out of  21 (38.1%) with B and 7 out of  19 (36.8%) 
with stage C were confirmed. No correlation was ob-
served between CLCr and MELD score (Figure 1). Also 
we detected no statistically significant differences in CLCr 
between Child-Pugh stages. Additionally, CLCr negatively 
correlated with CysC and Cr (rs = -0.415, P = 0.001; rs = 
-0.511, P < 0.001, respectively). 
There was a strong negative correlation between in-
creased CysC and decreased sNa+ in patients (r = -0.9, P 
= 0.002). In contrast, increased Cr values did not show a 
significant correlation with sNa+ concentration (P > 0.05). 
In patients with decreased urinary excretion of  sodium, 
CysC correlated negatively with uNa+ concentration (r = 
-0.748, P = 0.05), while Cr showed no significant relation 
with uNa+ (P > 0.05).
The mean GFR estimated using Cr (GFRCr) was 
113.5 mL/min per 1.73 m2. Lower values  of  GFRCr (< 90 
mL/min per 1.73 m2) were observed in 13 (20.6%) pa-
tients, and there was no statistically significant difference 
between Child-Pugh stages. Lower values of  GFRCr (< 
60 mL/min per 1.73 m2) were observed in 7 (11.1%) pa-
tients (P > 0.05). No significant correlation was observed 
in GFRCr between Child-Pugh stages (Table 1). Moreover, 
no significant correlation was detected between GFRCr 
and MELD score (Figure 1). 
Mean GFR based on CysC (GFRCys) was 77.6 mL/
min per 1.73 m2. Lower values of   GFRCys < 90 mL/min 
per 1.73 m2 were observed in 40 (63.5%) patients and 
GFRCys < 60 mL/min per 1.73 m2 in 16 (25.4%) patients, 
with no statistically significant difference between Child-
Pugh stages (P > 0.05).
Mean GFRCys in patients with normal values of  CysC 
was significantly higher than that in patients with in-
creased values of  CysC (94.8 ± 15.0 mL/min per 1.73 m2 
vs 53.5 ± 14.5 mL/min per 1.73 m2, P < 0.001, respec-
tively). Statistically significant differences in GFRCys be-
tween Child-Pugh stages were observed (Table 1). Post-
hoc comparisons showed differences in GFRCys between 
Child-Pugh stages A and B (P = 0.006) and between A 
and C (P = 0.005). Also, a significant correlation between 
GFRCys and MELD was determined (Figure 1). A moder-
ate degree of  correlation was found between GFRCys and 
GFRCr in patients with liver cirrhosis (rs = 0.64, P < 0.001). 
We identified significantly more patients with decreased 
GFR based on CysC than on Cr (P < 0.001). 
We noticed that RRI was significantly higher in cir-
rhotic patients than in controls (P = 0.005). RRI was 
already more increased in 27 (43%) patients with ascites 
when compared to 36 (57%) without ascites (P = 0.005).
Also, RRI was significantly influenced by Child-Pugh 
stage (Table 1). Comparisons showed markedly higher 
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Child-Pugh B and C. Similar to the previous findings, 
we confirmed that the values  of  CysC were significantly 
increased in advanced stages (Child-Pugh B and C) com-
pared to early stage (Child-Pugh A) of  liver cirrhosis, al-
though there was no significant difference between B and 
C stages. Additionally, we report a significant correlation 
between CysC and MELD score, advocating CysC as a 
valid marker of  liver insufficiency. Considering a variety 
of  non-renal factors influencing serum creatinine levels, 
and exclusion of  patients with HRS from the study, no 
significant correlation between Cr and MELD score was 
noted. Prognostic and clinical significance of  CysC is also 
shown in a recent study stating that CysC, serum sodium 
and prothrombin time were independent factors for pre-
dicting survival in patients with cirrhosis[31].
In our study, unlike Cr, CysC levels and serum and 
urinary concentration of  sodium demonstrated a strong 
negative correlation, suggesting a clinical relevance of  
CysC. These findings may be especially useful for moni-
toring patients with decompensated liver cirrhosis.
A study comparing GFRCys formula to GFRCr formula 
showed that CysC was more likely to predict the patients’ 
GFR below or above 60 mL/min per 1.73 m2[32]. Further-
more, the CysC showed a more significant correlation 
than serum Cr with GFR by 99mTc-DTPA technique[4,33,34]. 
Also, Coll et al[35] reported that serum CysC levels started 
to increase when GFR was 88 mL/min per 1.73 m2, 
while serum Cr level began to increase when GFR was 75 
mL/min per 1.73 m2.
However, Xirouchakis et al[36] compared 51Cr-EDTA 
with GFRCr and GFRCys formulas in 74 patients with cir-
rhosis, candidates for liver transplantation. They reported 
that estimated GFR in cirrhosis is not better based on 
CysC formulas compared with creatinine ones. 
In contrast, we identified significantly more patients 
with decreased glomerular filtration based on GFRCys 
compared to GFRCr. In regards to our findings, we sug-
gest GFRCys as a more sensitive parameter for assessment 
of  renal function in patients with liver cirrhosis.
The RRI is a sensitive marker of  intrarenal hemo-
dynamics and it has been reported to increase even in 
non-azotemic patients with cirrhosis[37]. Moreover, data 
suggest that normal serum Cr levels may be associated 
with a significantly decreased glomerular filtration rate 
and that more than 50% of  patients with end-stage liver 
disease and increased RRI have normal serum creatinine 
levels[38,39].
A recently published study reported that RRI was sig-
nificantly higher in Child-Pugh C patients than in Child-
Pugh B or A patients[23]. Findings from our research 
showed that RRI significantly increased from Child-Pugh 
stages A to C. Also, the RRI increased with an increase 
of  MELD score. These results indicate that RRI is di-
rectly influenced by liver insufficiency degree. 
In cirrhotic patients fluid accumulation can occur (in 
form of  pedal edema, minimal ascites and/or diuretic-
sensitive ascites), and renal blood flow is expected to 
decrease with GFR maintained at normal levels by in-
creased filtration fraction. The recognition and identifica-
tion of  these patients are particularly important for the 
early intervention and prevention of  progression of  renal 
diseases[40]. Accordingly, we aimed to examine this hemo-
dynamic disturbance by measuring RRI. 
To our knowledge, a small number of  studies have 
been published on possible correlations between CysC, 
GFR and arterial renal blood flow resistance. Cystatin C 
was compared to RRI in patients with viral C cirrhosis 
and authors reported significant positive correlations[22]. 
Ustundag et al[29] noted that serum CysC, but not serum 
creatinine or RRI measurement, correlated with GFR 
(GFR was estimated by technetium (99m)-diethylene tri-
amine pentaacetic acid renal scintigraphy), in each stage 
of  liver failure. Interestingly, our data showed that RRI 
significantly correlated with GFRCys, but not with GFRCr.
In conclusion, CysC may be a more reliable marker 
for liver insufficiency assessment. Additionally, RRI and 
CysC represent sensitive indicators of  renal dysfunction 
in patients with liver cirrhosis.
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Research frontiers
Some studies have indicated that serum CysC could be proposed as a marker 
of liver disease stage and a more sensitive indicator of renal function in patients 
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the mean value of renal arteries.
Peer review
The manuscript written by Culafic et al describes that cystatin C and renal 
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resistive index may be more reliable markers for assessment of liver and renal 
dysfunction in patients with liver cirrhosis. Conventionally, renal dysfunction is 
assessed by serum Cr or GFRCr. However, cystatin C and renal resistive index 
are more sensitive than those markers. The manuscript provides important 
information in the management of patients with liver cirrhosis.
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